Ranexa Run-Up Shows Breadth Of Biotech Rally On Wall Street
Executive Summary
CV Therapeutics is a quiet beneficiary of the FDA advisory committee decision regarding the risk of QT prolongation with GSK/Bayer's erectile dysfunction agent Levitra and Sanofi's benign prostatic hyperplasia treatment UroXatral
You may also be interested in...
Ranexa Restricted Angina Indication Would Require New Study, Cmte. Says
CV Therapeutics' Ranexa could receive a restricted indication for use in refractory angina patients with a new study in that population, FDA's Cardiovascular & Renal Drugs Advisory Committee said Dec. 9
Ranexa Restricted Angina Indication Would Require New Study, Cmte. Says
CV Therapeutics' Ranexa could receive a restricted indication for use in refractory angina patients with a new study in that population, FDA's Cardiovascular & Renal Drugs Advisory Committee said Dec. 9
Ranexa Advisory Cmte. Review Cancelled; User Fee Date May Be Extended
CV Therapeutics sees a Ranexa action letter or a user fee date extension as FDA's next possible steps following the cancellation of the angina agent's September review by FDA's Cardiovascular & Renal Drugs Advisory Committee